Scope of this article
This content is not diagnosis, prescribing, personal risk assessment or a treatment plan. Sources may be limited to a particular product, device, task, indication or study group.
This translation is provided for general access and has no recorded medical-language review.
Editorial general information — not a clinical-review record
Published: Updated: Publisher: Dr. Murat Toktamışoğlu
An exosome product and PRP are not the same: PRP is prepared from the person's blood, while extracellular-vesicle products may come from different cells, tissues or other biological sources and manufacturing processes. A small 2025 split-face study reported similar short-term changes with RF microneedling, but one trial is not proof of general equivalence.
This translation has no recorded clinical or medical-language review.
PRP varies with blood collection, anticoagulant, centrifugation, platelet and leukocyte content, activation and route. A product sold as exosomes varies with cell source, separation, carrier, vesicle identity, sterility and batch consistency. The exact study protocols, rather than two broad labels, therefore need comparison.
A split-face design can reduce person-level differences such as age, genetics and sun history. Yet a small sample, short follow-up, one center, a specific product and shared RF microneedling cannot resolve rare risk, long duration or the products' standalone effects. Finding no significant difference does not prove the approaches equivalent in every respect.
Discuss a defined skin target, the exact preparation or product record for each option, route, relevance of evidence to similar people, alternatives, cost and a complication plan. Autologous does not make PRP automatically effective, and cell-free does not make an exosome product automatically safe. Turkish regulatory status and no treatment require separate consideration.
This content is not diagnosis, prescribing, personal risk assessment or a treatment plan. Sources may be limited to a particular product, device, task, indication or study group.
These links are editorial starting points used to examine the article's boundaries.
Foppiani JA et al. · 2025
Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.
Editorial source — not a signed clinical review
Austin GK, Struble SL, Quatela VC · 2022
Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.
Editorial source — not a signed clinical review
Sanyal RD, Fabi SG · 2024
Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.
Editorial source — not a signed clinical review
U.S. Food and Drug Administration (FDA) · 2025
Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.
Editorial source — not a signed clinical review
Nancy Qin, Makayla Kochheiser, Izzet Akosman, David Dugue, Alex Raghunandan, Chetan Pavuluri, Carson Gundlach, Anna M Vaeth, Lucy Wei, Benjamin R Wesorick, David M Otterburn · 2025
Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.
Editorial source — not a signed clinical review
Lucas Kieling, Ana Terezinha Konzen, Rafaela Koehler Zanella, Denis Souto Valente · 2024
Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.
Editorial source — not a signed clinical review
B. Estupiñan, K. Ly and D. J. Goldberg · 2025
Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.
Editorial source — not a signed clinical review
J. C. Flores Rodríguez et al. · 2026
Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.
Editorial source — not a signed clinical review
International Society for Extracellular Vesicles consensus authors · 2024
Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.
Editorial source — not a signed clinical review